Human senescent fibroblasts trigger progressive lung fibrosis in mice

Cell senescence has recently emerged as a potentially relevant pathogenic mechanism in fibrosing interstitial lung diseases (f-ILDs), particularly in idiopathic pulmonary fibrosis. We hypothesized that senescent human fibroblasts may suffice to trigger a progressive fibrogenic reaction in the lung. To address this, senescent human lung fibroblasts, or their secretome (SASP), were instilled into the lungs of immunodeficient mice. We found that: (1) human senescent fibroblasts engraft in the lungs of immunodeficient mice and trigger progressive lung fibrosis associated to increasing levels of mouse senescent cells, whereas non-senescent fibroblasts do not trigger fibrosis; (2) the SASP of human senescent fibroblasts is pro-senescence and pro-fibrotic both in vitro when added to mouse recipient cells and in vivo when delivered into the lungs of mice, whereas the conditioned medium (CM) from non-senescent fibroblasts lacks these activities; and, (3) navitoclax, nintedanib and pirfenidone ameliorate lung fibrosis induced by senescent human fibroblasts in mice, albeit only navitoclax displayed senolytic activity. We conclude that human senescent fibroblasts, through their bioactive secretome, trigger a progressive fibrogenic reaction in the lungs of immunodeficient mice that includes the induction of paracrine senescence in the cells of the host, supporting the concept that senescent cells actively contribute to disease progression in patients with f-ILDs.

[1]  Michelle R. Dawson,et al.  Senescence-associated exosomes transfer miRNA-induced fibrosis to neighboring cells , 2023, Aging.

[2]  C. N. Coleman,et al.  Radiation-induced pulmonary fibrosis: roles of therapy-induced senescence and microRNAs , 2023, International journal of radiation biology.

[3]  G. Kuchel,et al.  Strategies for targeting senescent cells in human disease , 2021, Nature Aging.

[4]  C. Yao,et al.  Senescence of Alveolar Type 2 Cells Drives Progressive Pulmonary Fibrosis. , 2020, American journal of respiratory and critical care medicine.

[5]  V. Cottin,et al.  Spectrum of Fibrotic Lung Diseases. , 2020, The New England journal of medicine.

[6]  H. Popper,et al.  Senescence and autophagy in usual interstitial pneumonia of different etiology , 2020, Virchows Archiv.

[7]  L. Lerman,et al.  Transplanted senescent renal scattered tubular-like cells induce injury in the mouse kidney. , 2020, American journal of physiology. Renal physiology.

[8]  P. Bardin,et al.  Pirfenidone: Molecular Mechanisms and Potential Clinical Applications in Lung Disease. , 2020, American journal of respiratory cell and molecular biology.

[9]  Xiaodong Han,et al.  Epithelial cell senescence induces pulmonary fibrosis through Nanog-mediated fibroblast activation , 2019, Aging.

[10]  M. Loza,et al.  Identification and characterization of Cardiac Glycosides as senolytic compounds , 2019, Nature Communications.

[11]  Ivana V. Yang,et al.  Resequencing Study Confirms Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. , 2019, American journal of respiratory and critical care medicine.

[12]  Takeshi Johkoh,et al.  Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline , 2018, American journal of respiratory and critical care medicine.

[13]  C. Page,et al.  Use of animal models in IPF research. , 2018, Pulmonary pharmacology & therapeutics.

[14]  D. Allison,et al.  Senolytics Improve Physical Function and Increase Lifespan in Old Age , 2018, Nature Medicine.

[15]  N. LeBrasseur,et al.  Targeting Senescent Cells in Fibrosis: Pathology, Paradox, and Practical Considerations , 2018, Current Rheumatology Reports.

[16]  M. Rojas,et al.  IPF lung fibroblasts have a senescent phenotype. , 2017, American journal of physiology. Lung cellular and molecular physiology.

[17]  M. Selman,et al.  Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease , 2017, Nature Reviews Drug Discovery.

[18]  S. Melov,et al.  Unmasking Transcriptional Heterogeneity in Senescent Cells , 2017, Current Biology.

[19]  R. Chambers,et al.  An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis , 2017, American journal of respiratory cell and molecular biology.

[20]  A. Oberg,et al.  Cellular senescence mediates fibrotic pulmonary disease , 2017, Nature Communications.

[21]  L. Zender,et al.  The senescence-associated secretory phenotype induces cellular plasticity and tissue regeneration , 2017, Genes & development.

[22]  V. Lowe,et al.  Transplanted Senescent Cells Induce an Osteoarthritis-Like Condition in Mice , 2016, The journals of gerontology. Series A, Biological sciences and medical sciences.

[23]  Cory B. Giles,et al.  Identification of a novel senolytic agent, navitoclax, targeting the Bcl‐2 family of anti‐apoptotic factors , 2016, Aging cell.

[24]  A. Nordheim,et al.  Reduced Ets Domain-containing Protein Elk1 Promotes Pulmonary Fibrosis via Increased Integrin αvβ6 Expression* , 2016, The Journal of Biological Chemistry.

[25]  A. Budovsky,et al.  Cellular senescence-like features of lung fibroblasts derived from idiopathic pulmonary fibrosis patients , 2015, Aging.

[26]  G. Karakiulakis,et al.  Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis , 2014, Respiratory Research.

[27]  Manuel Serrano,et al.  Cellular senescence: from physiology to pathology , 2014, Nature Reviews Molecular Cell Biology.

[28]  K. Yamaguchi,et al.  Senescence-associated secretory phenotype in a mouse model of bleomycin-induced lung injury. , 2013, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[29]  Manuel Serrano,et al.  The Hallmarks of Aging , 2013, Cell.

[30]  J. Campisi Aging, cellular senescence, and cancer. , 2013, Annual review of physiology.

[31]  M. Rojas,et al.  Influence of age on wound healing and fibrosis , 2013, The Journal of pathology.

[32]  A. Agustí,et al.  Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. , 2012, American journal of respiratory and critical care medicine.

[33]  T. Wynn,et al.  Mechanisms of fibrosis: therapeutic translation for fibrotic disease , 2012, Nature Medicine.

[34]  Kristen M. Jacobsen,et al.  Age and sex dimorphisms contribute to the severity of bleomycin-induced lung injury and fibrosis. , 2011, American journal of physiology. Lung cellular and molecular physiology.

[35]  Thomas A. Wynn,et al.  Integrating mechanisms of pulmonary fibrosis , 2011, The Journal of experimental medicine.

[36]  L. Gleaves,et al.  Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis. , 2010, American journal of physiology. Lung cellular and molecular physiology.

[37]  H. Bolte,et al.  Standardized quantification of pulmonary fibrosis in histological samples. , 2008, BioTechniques.

[38]  C. Hogaboam,et al.  Murine models of pulmonary fibrosis. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[39]  J. Campisi,et al.  Cellular senescence: when bad things happen to good cells , 2007, Nature Reviews Molecular Cell Biology.

[40]  G. Hunninghake,et al.  Role of repeated lung injury and genetic background in bleomycin-induced fibrosis. , 2003, American journal of respiratory cell and molecular biology.

[41]  C Roskelley,et al.  A biomarker that identifies senescent human cells in culture and in aging skin in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[42]  S. Rosselot Idiopathic pulmonary fibrosis. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[43]  D. Warburton,et al.  The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? , 2008, The international journal of biochemistry & cell biology.